Oxidative stress and neuroinflammation in the story of Parkinson's disease: Could targeting these pathways write a good ending?

被引:94
作者
Hassanzadeh, Kambiz [1 ,2 ]
Rahimmi, Arman [2 ,3 ]
机构
[1] Kurdistan Univ Med Sci, Res Inst Hlth Dev, Cellular & Mol Res Ctr, Sanandaj, Iran
[2] Kurdistan Univ Med Sci, Physiol & Pharmacol Dept, Sch Med, Sanandaj, Iran
[3] Kurdistan Univ Med Sci, Student Res Comm, Sanandaj, Iran
关键词
antioxidants; neuroinflammation; oxidative stress; Parkinson's disease; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SUBSTANTIA-NIGRA; DOPAMINERGIC-NEURONS; N-ACETYLCYSTEINE; CELL-DEATH; RISK; AUTOPHAGY; INFLAMMATION; NEUROMELANIN; LRRK2;
D O I
10.1002/jcp.26865
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Although, current medications for Parkinson's disease can control and relief symptoms of the disease efficiently, they are unable to either prevent progression of the disease or maintain their controlling ability as a long-term medication. To find suitable adjuvant and/or alternative treatments, researchers have investigated antioxidative and anti-inflammatory approaches, since emerging evidence consider oxidative stress and neuroinflammation as leading causes of the development of Parkinson's disease. Here, how oxidative stress and neuroinflammation take part in Parkinson's disease pathogenesis was discussed based on featured studies in this context. Then, preclinical and clinical trial studies, which evaluated antioxidative and anti-inflammatory compounds' ability to treat Parkinson's disease, were reviewed.
引用
收藏
页码:23 / 32
页数:10
相关论文
共 98 条
[1]   OXIDANTS, ANTIOXIDANTS, AND THE DEGENERATIVE DISEASES OF AGING [J].
AMES, BN ;
SHIGENAGA, MK ;
HAGEN, TM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (17) :7915-7922
[2]  
Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25
[3]  
[Anonymous], 2014, J MAZANDARAN U MED S
[4]  
Arai H, 2006, HISTOL HISTOPATHOL, V21, P673, DOI 10.14670/HH-21.673
[5]   Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1β, and expression of caspase-11 in mice [J].
Arai, H ;
Furuya, T ;
Yasuda, T ;
Miura, M ;
Mizuno, Y ;
Mochizuki, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (49) :51647-51653
[6]   N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for? [J].
Arturo Martinez-Banaclocha, Marcos .
MEDICAL HYPOTHESES, 2012, 79 (01) :8-12
[7]   Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases [J].
Asanuma, M ;
Miyazaki, I ;
Ogawa, N .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (06) :695-700
[8]   LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives [J].
Atashrazm, Farzaneh ;
Dzamko, Nicolas .
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2016, 8 :177-189
[9]   A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease No Evidence of Benefit [J].
Beal, M. Flint ;
Oakes, David ;
Shoulson, Ira ;
Henchcliffe, Claire ;
Galpern, Wendy R. ;
Haas, Richard ;
Juncos, Jorge L. ;
Nutt, John G. ;
Voss, Tiffini Smith ;
Ravina, Bernard ;
Shults, Clifford M. ;
Helles, Karen ;
Snively, Victoria ;
Lew, Mark F. ;
Griebner, Brian ;
Watts, Arthur ;
Gao, Shan ;
Pourcher, Emmanuelle ;
Bond, Louisette ;
Kompoliti, Katie ;
Agarwal, Pinky ;
Sia, Cherissa ;
Jog, Mandar ;
Cole, Linda ;
Sultana, Munira ;
Kurlan, Roger ;
Richard, Irene ;
Deeley, Cheryl ;
Waters, Cheryl H. ;
Figueroa, Angel ;
Arkun, Ani ;
Brodsky, Matthew ;
Ondo, William G. ;
Hunter, Christine B. ;
Jimenez-Shahed, Joohi ;
Palao, Alicia ;
Miyasaki, Janis M. ;
Julie, S. O. ;
Tetrud, James ;
Reys, Liza ;
Smith, Katharine ;
Singer, Carlos ;
Blenke, Anita ;
Russell, David S. ;
Cotto, Candace ;
Friedman, Joseph H. ;
Lannon, Margaret ;
Zhang, Lin ;
Drasby, Edward ;
Kumar, Rajeev .
JAMA NEUROLOGY, 2014, 71 (05) :543-552
[10]   NSAID use and risk of Parkinson disease: a population-based case-control study [J].
Becker, C. ;
Jick, S. S. ;
Meier, C. R. .
EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (11) :1336-1342